---
title: "Moleculin Biotech | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286566040.md"
datetime: "2026-05-15T12:32:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286566040.md)
  - [en](https://longbridge.com/en/news/286566040.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286566040.md)
---

# Moleculin Biotech | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -3.54.

EBIT: As of FY2026 Q1, the actual value is USD -7.908 M.

### Segment Revenue

Moleculin Biotech, Inc. reported no revenues for the three months ended March 31, 2026, and March 31, 2025.

### Operational Metrics

#### Operating Expenses

Research and development (R&D) expenses for the three months ended March 31, 2026, were $5.4 million, an increase of $2.0 million compared to $3.4 million for the same period in 2025. This increase was primarily due to $1.4 million related to MIRACLE clinical trials in Europe and $0.3 million for additional nonclinical studies. General and administrative expenses were approximately $2.5 million for the quarter ended March 31, 2026, consistent with $2.5 million for the same period in 2025. Total operating expenses were $7.9 million for the three months ended March 31, 2026, up from $5.9 million in the prior year quarter.

#### Loss from Operations

Loss from operations was - $7.9 million for the three months ended March 31, 2026, compared to - $5.9 million for the same period in 2025.

#### Other Income/Expenses

The company reported a gain from change in fair value of warrant liability of $10.8 million, transaction costs allocated to warrant liabilities of - $0.7 million, and a loss on issuance of warrant liabilities of - $15.2 million for the three months ended March 31, 2026.

#### Net Loss

Net loss for the three months ended March 31, 2026, was - $12.8 million, compared to - $5.9 million for the same period in 2025. Net loss available to common stockholders was - $14.6 million for the first quarter of 2026, including a warrant deemed dividend of - $1.8 million, compared to - $5.9 million for the first quarter of 2025.

### Cash and Cash Equivalents

As of March 31, 2026, Moleculin Biotech, Inc. had cash and cash equivalents of approximately $10.3 million, up from $8.9 million as of December 31, 2025.

### Financing Transactions

During the first quarter of 2026, the company completed financing transactions that resulted in approximately $8.3 million in gross proceeds.

### Unique Operational Metrics

#### MIRACLE Trial Progress

Moleculin Biotech, Inc. achieved enrollment of the first 45 subjects in the pivotal MIRACLE Phase 2B/3 trial. A preliminary blinded composite complete remission (CRc) rate of 40% was observed at both the 30-subject and 45-subject marks.

### Outlook / Guidance

Moleculin Biotech, Inc. expects the first interim unblinding of data for 45 subjects in the MIRACLE trial in Q2 2026, with the recruitment of the 90th subject in Part A and subsequent unblinding anticipated in Q3 2026. The company plans to begin Part B of the MIRACLE trial and an Atlantic Health pancreatic cancer clinical trial in the second half of 2026. Management believes current cash resources, combined with recent financing proceeds, will fund planned operations into the third quarter of 2026.

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)

## Related News & Research

- [Moleculin Biotech Q1 net loss widens as R&D costs rise](https://longbridge.com/en/news/286567662.md)
- [Moleculin Nears First Unblinding in Pivotal MIRACLE Trial](https://longbridge.com/en/news/286263542.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [Bureau Veritas: All resolutions passed at May 19, 2026 Shareholders' Meeting.](https://longbridge.com/en/news/286946080.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)